. Hepatic metastases often occur in individuals having breast, colorectal, or neuroendocrine neoplastic tumors and usually indicate a poor prognosis for the patient (1). Radiotherapy or partial hepatectomy are often used for the treatment or removal of the hepatic tumors, respectively, but only 20%â€“30% of patients are eligible for these procedures because large or widespread lesions may occur in the organ or the patient may not benefit from either treatment due to the disease being at an advanced stage. In addition, many patients do not respond to the chemotherapeutic drugs used for the treatment of these lesions and suffer from many side effects as a result of the nonspecific cytotoxic or cytostatic activities exhibited by these drugs (1). Radioembolization of the tumors with 